Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors

ConclusionMTD was not reached. BI 836880 alone and in combination with ezabenlimab had a manageable safety profile with preliminary clinical activity in Japanese patients with advanced solid tumors.Trial registration and dateNCT03972150, registered on June 3, 2019.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research